Thus, using GLK+ Th17 cell as a biomarker will help with selection of patients in this subpopulation (GLKhighIL-17Ahigh) that are likely responsive to IL-17A blockade or GLK inhibitors, leading to precision medicine for SLE. This evidence concerns the gene IL17A and systemic lupus erythematosus.